Design, synthesis, and biological evaluation of crenatoside analogues as novel influenza neuraminidase inhibitors
Natural products, especially derived from TCMH, have been found to exert antiviral effects against influenza virus. Crenatoside, a phenylethanoid glycoside from Pogostemon cablin Benth, which has been shown as a novel effective NA inhibitor previously, is considered as the leading compound for our f...
Gespeichert in:
Veröffentlicht in: | European journal of medicinal chemistry 2016-02, Vol.109, p.199-205 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 205 |
---|---|
container_issue | |
container_start_page | 199 |
container_title | European journal of medicinal chemistry |
container_volume | 109 |
creator | Chen, Bao-Long Wang, Ya-Jing Guo, Hong Zeng, Guang-Yao |
description | Natural products, especially derived from TCMH, have been found to exert antiviral effects against influenza virus. Crenatoside, a phenylethanoid glycoside from Pogostemon cablin Benth, which has been shown as a novel effective NA inhibitor previously, is considered as the leading compound for our further SARs studies. This work presented design, synthesis of novel crenatoside analogues from readily available d-Glucose and l-rhamnose in a convergent manner. Furthermore, their biological activities and SARs were also investigated. Especially, compound 2 h showed impressive IC50 = 27.77 μg/mL against NAs, which is 3 folds more potent than the leading compound crenatoside (IC50 = 89.81 μg/mL). These results would promise their therapeutic potential for influenza disease.
[Display omitted]
•The synthesis of isocrenatoside analogues as novel NA inhibitors was accomplished.•The new compounds were fully characterized by NMR and ESI-MS spectroscopy.•Some compounds exhibited moderate activities and compound 2 h was the best with IC50 = 27.77 μg/ml against NAs.•The structure-activity relationships of new isocrenatoside analogues was discussed. |
doi_str_mv | 10.1016/j.ejmech.2015.12.031 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1762344311</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0223523415304177</els_id><sourcerecordid>1762344311</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-7590d636ebabf3f2956db22c71b71314edd9a998b52b336bb81312b90e86fc653</originalsourceid><addsrcrecordid>eNp9kElLxDAUgIMoOi7_QCRHD7ZmadP2Iog7CF70HLK8OhnaRJN2QH-9kVGPnt7j8b3tQ-iYkpISKs5XJaxGMMuSEVqXlJWE0y20oI1oC87qahstCGO8qBmv9tB-SitCSC0I2UV7TDRN1bF2gd6vIblXf4bTh5-WOU9nWHmLtQtDeHVGDRjWapjV5ILHoccmgldTSM5CBlWGZkhYJezDGgbsfD_M4D8V9jBHNTrvrEqQ60un3RRiOkQ7vRoSHP3EA_Rye_N8dV88Pt09XF0-FoYLNhVN3REruACtdM971tXCasZMQ3VDOa3A2k51XatrpjkXWre5ynRHoBW9ETU_QKebuW8xvOcbJzm6ZGAYlIcwJ5lFZTMVpzSj1QY1MaQUoZdv0Y0qfkhK5LdsuZIb2fJbtqRMZtm57eRnw6xHsH9Nv3YzcLEBIP-5dhBlMg68AesimEna4P7f8AUy8ZQL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1762344311</pqid></control><display><type>article</type><title>Design, synthesis, and biological evaluation of crenatoside analogues as novel influenza neuraminidase inhibitors</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Chen, Bao-Long ; Wang, Ya-Jing ; Guo, Hong ; Zeng, Guang-Yao</creator><creatorcontrib>Chen, Bao-Long ; Wang, Ya-Jing ; Guo, Hong ; Zeng, Guang-Yao</creatorcontrib><description>Natural products, especially derived from TCMH, have been found to exert antiviral effects against influenza virus. Crenatoside, a phenylethanoid glycoside from Pogostemon cablin Benth, which has been shown as a novel effective NA inhibitor previously, is considered as the leading compound for our further SARs studies. This work presented design, synthesis of novel crenatoside analogues from readily available d-Glucose and l-rhamnose in a convergent manner. Furthermore, their biological activities and SARs were also investigated. Especially, compound 2 h showed impressive IC50 = 27.77 μg/mL against NAs, which is 3 folds more potent than the leading compound crenatoside (IC50 = 89.81 μg/mL). These results would promise their therapeutic potential for influenza disease.
[Display omitted]
•The synthesis of isocrenatoside analogues as novel NA inhibitors was accomplished.•The new compounds were fully characterized by NMR and ESI-MS spectroscopy.•Some compounds exhibited moderate activities and compound 2 h was the best with IC50 = 27.77 μg/ml against NAs.•The structure-activity relationships of new isocrenatoside analogues was discussed.</description><identifier>ISSN: 0223-5234</identifier><identifier>EISSN: 1768-3254</identifier><identifier>DOI: 10.1016/j.ejmech.2015.12.031</identifier><identifier>PMID: 26774928</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Antiviral Agents - chemistry ; Antiviral Agents - pharmacology ; Caffeic Acids - chemistry ; Caffeic Acids - pharmacology ; Crenatoside derivatives ; Design ; Drug Design ; Enzyme Inhibitors - chemistry ; Enzyme Inhibitors - pharmacology ; Glucosides - chemistry ; Glucosides - pharmacology ; Humans ; Influenza A virus - drug effects ; Influenza A virus - enzymology ; Influenza A Virus, H1N1 Subtype - drug effects ; Influenza A Virus, H1N1 Subtype - enzymology ; Influenza virus ; Influenza, Human - drug therapy ; Influenza, Human - virology ; Models, Molecular ; Neuraminidase - antagonists & inhibitors ; Neuraminidase - metabolism ; Neuraminidases inhibitors ; Structure-Activity Relationship ; Synthesis</subject><ispartof>European journal of medicinal chemistry, 2016-02, Vol.109, p.199-205</ispartof><rights>2016 Elsevier Masson SAS</rights><rights>Copyright © 2016 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-7590d636ebabf3f2956db22c71b71314edd9a998b52b336bb81312b90e86fc653</citedby><cites>FETCH-LOGICAL-c362t-7590d636ebabf3f2956db22c71b71314edd9a998b52b336bb81312b90e86fc653</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0223523415304177$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26774928$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Bao-Long</creatorcontrib><creatorcontrib>Wang, Ya-Jing</creatorcontrib><creatorcontrib>Guo, Hong</creatorcontrib><creatorcontrib>Zeng, Guang-Yao</creatorcontrib><title>Design, synthesis, and biological evaluation of crenatoside analogues as novel influenza neuraminidase inhibitors</title><title>European journal of medicinal chemistry</title><addtitle>Eur J Med Chem</addtitle><description>Natural products, especially derived from TCMH, have been found to exert antiviral effects against influenza virus. Crenatoside, a phenylethanoid glycoside from Pogostemon cablin Benth, which has been shown as a novel effective NA inhibitor previously, is considered as the leading compound for our further SARs studies. This work presented design, synthesis of novel crenatoside analogues from readily available d-Glucose and l-rhamnose in a convergent manner. Furthermore, their biological activities and SARs were also investigated. Especially, compound 2 h showed impressive IC50 = 27.77 μg/mL against NAs, which is 3 folds more potent than the leading compound crenatoside (IC50 = 89.81 μg/mL). These results would promise their therapeutic potential for influenza disease.
[Display omitted]
•The synthesis of isocrenatoside analogues as novel NA inhibitors was accomplished.•The new compounds were fully characterized by NMR and ESI-MS spectroscopy.•Some compounds exhibited moderate activities and compound 2 h was the best with IC50 = 27.77 μg/ml against NAs.•The structure-activity relationships of new isocrenatoside analogues was discussed.</description><subject>Antiviral Agents - chemistry</subject><subject>Antiviral Agents - pharmacology</subject><subject>Caffeic Acids - chemistry</subject><subject>Caffeic Acids - pharmacology</subject><subject>Crenatoside derivatives</subject><subject>Design</subject><subject>Drug Design</subject><subject>Enzyme Inhibitors - chemistry</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Glucosides - chemistry</subject><subject>Glucosides - pharmacology</subject><subject>Humans</subject><subject>Influenza A virus - drug effects</subject><subject>Influenza A virus - enzymology</subject><subject>Influenza A Virus, H1N1 Subtype - drug effects</subject><subject>Influenza A Virus, H1N1 Subtype - enzymology</subject><subject>Influenza virus</subject><subject>Influenza, Human - drug therapy</subject><subject>Influenza, Human - virology</subject><subject>Models, Molecular</subject><subject>Neuraminidase - antagonists & inhibitors</subject><subject>Neuraminidase - metabolism</subject><subject>Neuraminidases inhibitors</subject><subject>Structure-Activity Relationship</subject><subject>Synthesis</subject><issn>0223-5234</issn><issn>1768-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kElLxDAUgIMoOi7_QCRHD7ZmadP2Iog7CF70HLK8OhnaRJN2QH-9kVGPnt7j8b3tQ-iYkpISKs5XJaxGMMuSEVqXlJWE0y20oI1oC87qahstCGO8qBmv9tB-SitCSC0I2UV7TDRN1bF2gd6vIblXf4bTh5-WOU9nWHmLtQtDeHVGDRjWapjV5ILHoccmgldTSM5CBlWGZkhYJezDGgbsfD_M4D8V9jBHNTrvrEqQ60un3RRiOkQ7vRoSHP3EA_Rye_N8dV88Pt09XF0-FoYLNhVN3REruACtdM971tXCasZMQ3VDOa3A2k51XatrpjkXWre5ynRHoBW9ETU_QKebuW8xvOcbJzm6ZGAYlIcwJ5lFZTMVpzSj1QY1MaQUoZdv0Y0qfkhK5LdsuZIb2fJbtqRMZtm57eRnw6xHsH9Nv3YzcLEBIP-5dhBlMg68AesimEna4P7f8AUy8ZQL</recordid><startdate>20160215</startdate><enddate>20160215</enddate><creator>Chen, Bao-Long</creator><creator>Wang, Ya-Jing</creator><creator>Guo, Hong</creator><creator>Zeng, Guang-Yao</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160215</creationdate><title>Design, synthesis, and biological evaluation of crenatoside analogues as novel influenza neuraminidase inhibitors</title><author>Chen, Bao-Long ; Wang, Ya-Jing ; Guo, Hong ; Zeng, Guang-Yao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-7590d636ebabf3f2956db22c71b71314edd9a998b52b336bb81312b90e86fc653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antiviral Agents - chemistry</topic><topic>Antiviral Agents - pharmacology</topic><topic>Caffeic Acids - chemistry</topic><topic>Caffeic Acids - pharmacology</topic><topic>Crenatoside derivatives</topic><topic>Design</topic><topic>Drug Design</topic><topic>Enzyme Inhibitors - chemistry</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Glucosides - chemistry</topic><topic>Glucosides - pharmacology</topic><topic>Humans</topic><topic>Influenza A virus - drug effects</topic><topic>Influenza A virus - enzymology</topic><topic>Influenza A Virus, H1N1 Subtype - drug effects</topic><topic>Influenza A Virus, H1N1 Subtype - enzymology</topic><topic>Influenza virus</topic><topic>Influenza, Human - drug therapy</topic><topic>Influenza, Human - virology</topic><topic>Models, Molecular</topic><topic>Neuraminidase - antagonists & inhibitors</topic><topic>Neuraminidase - metabolism</topic><topic>Neuraminidases inhibitors</topic><topic>Structure-Activity Relationship</topic><topic>Synthesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Bao-Long</creatorcontrib><creatorcontrib>Wang, Ya-Jing</creatorcontrib><creatorcontrib>Guo, Hong</creatorcontrib><creatorcontrib>Zeng, Guang-Yao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Bao-Long</au><au>Wang, Ya-Jing</au><au>Guo, Hong</au><au>Zeng, Guang-Yao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Design, synthesis, and biological evaluation of crenatoside analogues as novel influenza neuraminidase inhibitors</atitle><jtitle>European journal of medicinal chemistry</jtitle><addtitle>Eur J Med Chem</addtitle><date>2016-02-15</date><risdate>2016</risdate><volume>109</volume><spage>199</spage><epage>205</epage><pages>199-205</pages><issn>0223-5234</issn><eissn>1768-3254</eissn><abstract>Natural products, especially derived from TCMH, have been found to exert antiviral effects against influenza virus. Crenatoside, a phenylethanoid glycoside from Pogostemon cablin Benth, which has been shown as a novel effective NA inhibitor previously, is considered as the leading compound for our further SARs studies. This work presented design, synthesis of novel crenatoside analogues from readily available d-Glucose and l-rhamnose in a convergent manner. Furthermore, their biological activities and SARs were also investigated. Especially, compound 2 h showed impressive IC50 = 27.77 μg/mL against NAs, which is 3 folds more potent than the leading compound crenatoside (IC50 = 89.81 μg/mL). These results would promise their therapeutic potential for influenza disease.
[Display omitted]
•The synthesis of isocrenatoside analogues as novel NA inhibitors was accomplished.•The new compounds were fully characterized by NMR and ESI-MS spectroscopy.•Some compounds exhibited moderate activities and compound 2 h was the best with IC50 = 27.77 μg/ml against NAs.•The structure-activity relationships of new isocrenatoside analogues was discussed.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>26774928</pmid><doi>10.1016/j.ejmech.2015.12.031</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0223-5234 |
ispartof | European journal of medicinal chemistry, 2016-02, Vol.109, p.199-205 |
issn | 0223-5234 1768-3254 |
language | eng |
recordid | cdi_proquest_miscellaneous_1762344311 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Antiviral Agents - chemistry Antiviral Agents - pharmacology Caffeic Acids - chemistry Caffeic Acids - pharmacology Crenatoside derivatives Design Drug Design Enzyme Inhibitors - chemistry Enzyme Inhibitors - pharmacology Glucosides - chemistry Glucosides - pharmacology Humans Influenza A virus - drug effects Influenza A virus - enzymology Influenza A Virus, H1N1 Subtype - drug effects Influenza A Virus, H1N1 Subtype - enzymology Influenza virus Influenza, Human - drug therapy Influenza, Human - virology Models, Molecular Neuraminidase - antagonists & inhibitors Neuraminidase - metabolism Neuraminidases inhibitors Structure-Activity Relationship Synthesis |
title | Design, synthesis, and biological evaluation of crenatoside analogues as novel influenza neuraminidase inhibitors |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T14%3A15%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Design,%20synthesis,%20and%20biological%20evaluation%20of%20crenatoside%20analogues%20as%20novel%20influenza%20neuraminidase%20inhibitors&rft.jtitle=European%20journal%20of%20medicinal%20chemistry&rft.au=Chen,%20Bao-Long&rft.date=2016-02-15&rft.volume=109&rft.spage=199&rft.epage=205&rft.pages=199-205&rft.issn=0223-5234&rft.eissn=1768-3254&rft_id=info:doi/10.1016/j.ejmech.2015.12.031&rft_dat=%3Cproquest_cross%3E1762344311%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1762344311&rft_id=info:pmid/26774928&rft_els_id=S0223523415304177&rfr_iscdi=true |